AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved SKYRIZI® (risankizumab-rzaa) for the treatment of children six years of age and older with ...

In the full intention-to-treat population for the efficacy analysis, 230 of 255 patients (90.2%) who received risankizumab and 193 of 265 patients (72.8%) who received ustekinumab completed all the ...

Discover comprehensive details about Risankizumab, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated prescription ...

On Friday, the U.S. Food and Drug Administration (FDA) approved AbbVie Inc.’s ABBV SKYRIZI (risankizumab-rzaa) for children ...

The FDA approved risankizumab-rzaa for children aged at least 6 years with moderate to severe plaque psoriasis who are ...

COPENHAGEN, Denmark — Risankizumab (Skyrizi, AbbVie) shows noninferiority for clinical remission at week 24, and superiority of endoscopic remission at week 48 when compared with ustekinumab (Stelara) ...

Risankizumab is an effective treatment option for patients with psoriatic arthritis (PsA), according to a recent meta-analysis. Risankizumab showed superior efficacy across multiple outcomes compared ...

The evaluation committee considered evidence submitted by AbbVie, a review of this submission by the external assessment group (EAG), and responses from stakeholders. See the committee papers for full ...

NORTH CHICAGO, Ill., June 23, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Commission (EC) has approved SKYRIZI® (risankizumab) for the treatment of children and ...

European Commission Expands Skyrizi Label to Younger Patients AbbVie (NYSE:ABBV) has received approval from the European ...

SKYRIZI (risankizumab-rzaa) is now approved for patients six years of age and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis Approval ...